Prospective study of the long‐term efficacy and safety of lansoprazole in patients with the Zollinger‐Ellison syndrome

Alimentary Pharmacology & Therapeutics

Volumn 7, Issue , 1993, Pages 41-50

  JENSEN, R T ^a   METZ, D C ^a   KOVIACK, P D ^a   FEIGENBAUM, K M ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIN; LANSOPRAZOLE;

ADULT; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; ZOLLINGER ELLISON SYNDROME;

ADULT; AGED; ALANINE TRANSAMINASE; ANTI-ULCER AGENTS; ASPARTATE AMINOTRANSFERASES; DRUG ADMINISTRATION SCHEDULE; FASTING; FEMALE; FOLLOW-UP STUDIES; GASTRINS; HUMAN; MALE; MIDDLE AGE; OMEPRAZOLE; PROSPECTIVE STUDIES; ZOLLINGER-ELLISON SYNDROME;

EID: 0027536343     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.1993.tb00588.x     Document Type: Article

References (39)

1. Gastrinoma
2. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas
3. Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric hypersecretory states
4. Medical management of patients with Zollinger‐Ellison syndrome who have had previous gastric surgery: A prospective study
5. Reflux esophagitis in patients with Zollinger‐Ellison syndrome
6. syndrome
7. +) ATPase
8. Omeprazole
9. Omeprazole
10. Use of omeprazole in patients with Zollinger‐Ellison syndrome
11. Zollinger‐Ellison syndrome. Clinical presentation, pathology, diagnosis and treatment
12. Omeprazole in the Zollinger‐Ellison syndrome
13. Long‐term efficacy and safety of omeprazole in patients with Zollinger‐Ellison syndrome: A prospective study
14. Omeprazole in the treatment of Zollinger‐Ellison syndrome: A 4‐year international study
15. Antisecretory activity of AG1749, a proton pump inhibitor
16. Antisecretory and antiulcer activities of a novel proton pump inhibitor AG‐1749 in dogs and rats
17. Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG 1749 in isolated canine parietal cells
18. Antiulcer activity of AG‐1749, a proton pump inhibitor
19. Is lansoprazole as effective as omeprazole in patients with Zollinger‐Ellison syndrome (ZES)
20. Omeprazole: Effective, convenient therapy for Zollinger‐Ellison syndrome
21. Pharmacokinetics of oral and intravenous omeprazole in patients with Zollinger‐Ellison syndrome
22. Secretin and calcium provocative tests in Zollinger‐Ellison syndrome
23. Current management of Zollinger‐Ellison syndrome
24. Reliability of symptoms in assessing control of gastric acid secretion in patients with Zollinger‐Ellison syndrome
25. Current maintenance doses of omeprazole in Zollinger‐Ellison syndrome are too high
26. Curative resection in patients with Zollinger‐Ellison syndrome: Results of a 10 year prospective study
27. Famotidine in the therapy of gastric hypersecretory states
28. 24 hour intragastric acidity under AG 1749–a newly developed proton pump inhibitor
29. Human gastric acid secretion following repeated doses of AG‐1749
30. Basis for failure of cimetidine in patients with Zollinger‐Ellison syndrome
31. Twenty‐four hour intragastric acidity and plasma gastrin concentrations before and during treatment with either ranitidine or omeprazole
32. US Experience with omeprazole in duodenal ulcer–multicenter double‐blind comparative study with ranitidine
33. The effect of Zollinger‐Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells
34. Gastric endocrine cell behavior in Zollinger‐Ellison patients upon long‐term antisecretory treatment
35. Toxicological studies on omeprazole
36. Gastrinoma as a model for prolonged hypergastrinemia in man
37. Clinical implications of hypergastrinemia